Homepage Top Section1

Both firms have worked together to develop a vaccine candidate, which applies the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s pandemic adjuvant

AstraZeneca has initiated a phase 1 trial of a monoclonal antibody combination called AZD7442, which is being developed for the prevention and treatment of Covid-19. Dubbed as NCT04507256,

The manufacturing of the AZD1222 vaccine candidate will be taken up at Catalent’s commercial gene therapy manufacturing plant in Harmans, Maryland. Catalent said that it will prepare the

TYVYT, which was co-developed by Innovent and Lilly in China, is an anti-PD-1 monoclonal antibody immuno-oncology medicine. The duo began selling the drug in the country since 2019

Licensed from the Oxford University, the AZD1222 vaccine candidate had delivered strong immune responses against the Covid-19 causing SARS-CoV-2 virus in all participants in a phase I/II trial

Both companies have not disclosed the financial terms of the deal. The research will include the application of GeneCentric’s advanced RNA-based molecular profiling platform to illustrate the potential

The acquisition of KaNDy Therapeutics will allow Bayer to expand its drug development pipeline in women’s healthcare. The deal also allows KaNDy Therapeutics to secure potential milestone payments

BLENREP has been approved as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have secured at least four prior therapies including an anti-CD38

The companies said that rapid recovery was seen in patients on ventilators and extracorporeal membrane oxygenation (ECMO) and having severe medical comorbidities following three days of treatment with